The Florida federal judge overseeing the Zantac multidistrict litigation has dismissed all claims, without leave to amend, against manufacturers of ranitidine, the generic or store brand version of the prescription medication Zantac, citing federal law preemption. On July 8, U.S. District Judge Robin Rosenberg dismissed plaintiffs’ claims that the generic drug manufacturers and suppliers had failed to warn consumers about the risks of taking ranitidine, observing that federal law precluded them from adding warnings or changing the labels from those that had already been approved for the brand name version of the drug, Zantac. Judge Rosenberg had also dismissed the claims based on design defect based on the same federal impossibility preemption rationale – generic manufacturers and suppliers are obligated only to label their products with the same label used on the name brand.
This ruling is the latest in the Zantac MDL brought by consumers who allege that Zantac, a popular heartburn and gastric treatment medication, is inherently dangerous because it contains NDMA, or N-nitrosodimethylamine, a carcinogen created when the medication is stored at higher than room temperature. According to the Order Granting the Generic Defendants’ Motion to Dismiss issued on July 8, Valisure LLC and ValisureRX LLC, a pharmacy and testing laboratory, filed a Citizen Petition on September 9, 2019, calling for the recall of all ranitidine products due to high levels of NDMA in the products.
The post Litigation Update: Claims Dismissed Against Manufacturers of Generic Zantac appeared first on Verus LLC.